首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   4074篇
  免费   179篇
  国内免费   16篇
耳鼻咽喉   66篇
儿科学   94篇
妇产科学   22篇
基础医学   452篇
口腔科学   81篇
临床医学   218篇
内科学   793篇
皮肤病学   38篇
神经病学   464篇
特种医学   212篇
外科学   809篇
综合类   26篇
预防医学   82篇
眼科学   46篇
药学   269篇
中国医学   6篇
肿瘤学   591篇
  2023年   27篇
  2022年   54篇
  2021年   70篇
  2020年   46篇
  2019年   51篇
  2018年   81篇
  2017年   60篇
  2016年   71篇
  2015年   66篇
  2014年   78篇
  2013年   114篇
  2012年   202篇
  2011年   213篇
  2010年   132篇
  2009年   128篇
  2008年   183篇
  2007年   212篇
  2006年   225篇
  2005年   200篇
  2004年   205篇
  2003年   173篇
  2002年   193篇
  2001年   136篇
  2000年   132篇
  1999年   150篇
  1998年   46篇
  1997年   52篇
  1996年   42篇
  1995年   57篇
  1994年   34篇
  1993年   37篇
  1992年   85篇
  1991年   84篇
  1990年   74篇
  1989年   57篇
  1988年   51篇
  1987年   52篇
  1986年   62篇
  1985年   53篇
  1984年   37篇
  1983年   35篇
  1982年   22篇
  1981年   13篇
  1980年   15篇
  1979年   28篇
  1978年   16篇
  1977年   12篇
  1974年   14篇
  1973年   17篇
  1969年   13篇
排序方式: 共有4269条查询结果,搜索用时 15 毫秒
91.
92.
93.
94.
95.
TAFRO syndrome is a systemic inflammatory, lymphoproliferative disorder, but the pathophysiology of the disease is unknown. It is typically characterized by thrombocytopenia, anasarca, a fever, reticulin fibrosis, renal dysfunction, and organomegaly. However, other manifestations have been also reported. We encountered a 43-year-old man with TAFRO syndrome who showed mediastinal panniculitis, liver damage, and adrenal lesions in addition to the core signs. He achieved complete remission with combination therapy of corticosteroids, tocilizumab, and cyclosporin, and remission was maintained even after drug discontinuation at 15 months. Atypical manifestations and complete remission of TAFRO syndrome were remarkable features of our case.  相似文献   
96.
The pterygoid process undergoes ossification of both the cartilage and membrane. However, few studies have attempted to explore the sequential development of the pterygoid process. Using histological examination, we performed morphological observations of the pterygoid process and surrounding tissue. ICR mice at embryonic days 13.5–18.0 and postnatal day 0 were used for morphological observations of the pterygoid process. By embryonic day 14.5, a mesenchymal cell condensation forming the anlage of the future medial pterygoid process differentiated into osteoid-like tissue and cartilage. At embryonic days 15.5–16.5, cartilage cells were clearly evident in the medial pterygoid process. In the medial pterygoid process, a bone collar was evident and calcified bone tissue surrounded the cartilage. At this point, a mesenchymal cell condensation formed the anlage of the pterygoid hamulus. At embryonic days 17.0–18.0, the cartilages were located along the lower and posterior border of the medial pterygoid process. A metachromatically stained matrix first became detectable around cells located in the pterygoid hamulus. On the other hand, at embryonic day 13.5, a metachromatically stained matrix was already evident in the space between the flattened cells in the lateral pterygoid process. At embryonic day 17.0, a hypertrophic cell zone had clearly formed in the diaphysis. On the basis of our present investigation, the lateral pterygoid process can be classified as primary cartilage, whereas the medial pterygoid process can be classified as secondary cartilage. Furthermore, it was found that the pterygoid hamulus is formed latest in the medial pterygoid process.  相似文献   
97.
98.
99.
100.
Thrombomodulin (TM) is an endothelial anticoagulant cofactor that promotes thrombin-mediated formation of activated protein C (APC). We have found that the N-terminal lectin-like domain (D1) of TM has unique antiinflammatory properties. TM, via D1, binds high-mobility group-B1 DNA-binding protein (HMGB1), a factor closely associated with necrotic cell damage following its release from the nucleus, thereby preventing in vitro leukocyte activation, in vivo UV irradiation-induced cutaneous inflammation, and in vivo lipopolysaccharide-induced lethality. Our data also demonstrate antiinflammatory properties of a peptide spanning D1 of TM and suggest its therapeutic potential. These findings highlight a novel mechanism, i.e., sequestration of mediators, through which an endothelial cofactor, TM, suppresses inflammation quite distinctly from its anticoagulant cofactor activity, thereby preventing the interaction of these mediators with cell surface receptors on effector cells in the vasculature.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号